Telo Genomics Corp (TSE:TELO) has released an update.
Telo Genomics Corp. showcased its AI-driven CellSelect-Pro tool at the prestigious ASCO 2024 conference, highlighting its ability to improve accuracy and reduce costs in myeloma diagnostic tests. The tool, which is now part of Telo’s TeloViewSMM product and an ongoing clinical trial, has been validated with over 90% accuracy in identifying myeloma cells. The company’s recent publication in the American Journal of Hematology further underscores the potential of TeloView technology in predicting the progression of smoldering multiple myeloma.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.